A detailed history of D. E. Shaw & Co., Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 626,907 shares of ABBV stock, worth $113 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
626,907
Holding current value
$113 Million
% of portfolio
0.12%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $47.8 Million - $58.1 Million
-291,724 Reduced 31.76%
626,907 $124 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $27.7 Million - $32.3 Million
178,932 Added 24.19%
918,631 $158 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $52.1 Million - $59.4 Million
-326,055 Reduced 30.59%
739,699 $135 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $7.44 Million - $8.38 Million
-54,054 Reduced 4.83%
1,065,754 $165 Million
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $72.7 Million - $84.1 Million
-543,840 Reduced 32.69%
1,119,808 $167 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $203 Million - $253 Million
1,532,290 Added 1166.5%
1,663,648 $224 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $739,246 - $851,352
5,112 Added 4.05%
131,358 $20.9 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $1.61 Million - $1.93 Million
11,663 Added 10.18%
126,246 $20.4 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $1.71 Million - $1.97 Million
12,772 Added 12.54%
114,583 $15.4 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $24.1 Million - $30.6 Million
-174,802 Reduced 63.19%
101,811 $15.6 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $327,442 - $406,263
2,481 Added 0.91%
276,613 $44.8 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $3.65 Million - $4.62 Million
33,958 Added 14.14%
274,132 $37.1 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $17.8 Million - $20.3 Million
167,678 Added 231.29%
240,174 $25.9 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $5.5 Million - $6.12 Million
52,250 Added 258.08%
72,496 $8.17 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $1.3 Million - $1.43 Million
12,672 Added 167.31%
20,246 $2.19 Million
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $50.8 Million - $68.6 Million
-630,923 Reduced 98.81%
7,574 $812,000
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $71.6 Million - $84 Million
-833,134 Reduced 56.61%
638,497 $55.9 Million
Q2 2020

Aug 14, 2020

SELL
$73.37 - $98.18 $170 Million - $227 Million
-2,314,812 Reduced 61.13%
1,471,631 $144 Million
Q1 2020

May 15, 2020

SELL
$64.5 - $97.79 $20 Million - $30.3 Million
-309,916 Reduced 7.57%
3,786,443 $288 Million
Q4 2019

Feb 14, 2020

SELL
$72.13 - $90.25 $84.8 Million - $106 Million
-1,175,131 Reduced 22.29%
4,096,359 $363 Million
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $70.5 Million - $84.8 Million
-1,119,613 Reduced 17.52%
5,271,490 $399 Million
Q2 2019

Aug 14, 2019

BUY
$65.7 - $83.98 $19.5 Million - $24.9 Million
296,368 Added 4.86%
6,391,103 $465 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $384 Million - $452 Million
4,979,335 Added 446.42%
6,094,735 $491 Million
Q4 2018

Feb 14, 2019

SELL
$77.85 - $96.01 $51.4 Million - $63.4 Million
-660,112 Reduced 37.18%
1,115,400 $103 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $30 Million - $33.3 Million
-336,902 Reduced 15.95%
1,775,512 $168 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $37.4 Million - $44.3 Million
416,639 Added 24.57%
2,112,414 $196 Million
Q1 2018

May 15, 2018

BUY
$92.01 - $123.21 $65.2 Million - $87.3 Million
708,775 Added 71.81%
1,695,775 $161 Million
Q4 2017

Feb 14, 2018

SELL
$89.56 - $98.21 $11.5 Million - $12.6 Million
-128,673 Reduced 11.53%
987,000 $95.5 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $77.9 Million - $99.5 Million
1,115,673
1,115,673 $99.1 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.